Lyudmila Bazhenova, M.d.

This early-stage study tested a new drug, plinabulin, combined with an existing immunotherapy (nivolumab) for people with advanced non-small cell lung cancer that had worsened after chemotherapy. The main goal was to find the safest and most effective dose of the new combination.…